Understanding **How effective is Pritelivir?** A review of clinical trial results
•
3 min read
In a head-to-head Phase 2 clinical trial, the experimental drug pritelivir significantly outperformed the standard-of-care medication valacyclovir for suppressing genital herpes simplex virus (HSV) shedding. This promising new antiviral offers a novel mechanism of action, addressing a critical need for new and more effective **Pritelivir** treatment options, particularly for immunocompromised patients with drug-resistant infections.
